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Abstract 
Prostate cancer is the sixth deadliest cancer worldwide due to its metastatic ability, rendering 
conventional treatment futile. Editing target oncogenes with the help of CRISPR/Cas9 is 
gaining recognition as promising treatment modality. However, the implementation of 
CRISPR/Cas9 in the clinical setting remains difficult due to challenges in delivery to target 
tissue. Therefore, this literature review focuses on exploring nanocarrier suitable for 
CRISPR/Cas9 delivery. The method used to assemble this literature review is by performing 
a comprehensive literature search with corresponding keywords. Results show that targeted 
delivery system of CRISPR/Cas9 using cationic liposome conjugated with RNA aptamer is 
an excellent candidate. Modification of cationic liposome, a well-established nanocarrier, with 
PEG and RNA aptamer as targeting ligand increases specificity, efficiency, stability, and 
circulation time in bloodstream. However, further research is still needed to confirm these 
findings for future implementation of this technology as prostate cancer therapy. 
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Introduction 
Prostate cancer affects approximately 
899,000 men worldwide. In Asia, the 
incidence of prostate cancer ranges from 1 
per 100,000 men until 53.3 per 100,000 
men, making it the sixth leading cause of 
mortality by cancer worldwide.1,2  
Prostate cancer is capable of metastasizing 
to distant regions of the body, such as the 
bone and the skin. While metastatic prostate 
cancer is traditionally treated with androgen 
deprivation therapy, the late-stage tumor 
usually contains androgen deprivation-
resistant (castration-resistant) cells which  
 
will emerge after elimination of castration-
sensitive cells through androgen deprivation 
therapy. This phenomenon is very 
problematic and often life threatening.3  
The advancements in medical science have 
provided a better insight into the genetic 
basis of cancer. Genetic alterations involved 
in the cancer progression have been 
identified, with activation of oncogenes and 
inactivation of cell cycle regulators playing 
critical role. Accordingly, gene-based 
approach for the molecular therapy of 
cancer is emerging as a novel method of the 
treatment. Central to this approach is the 
modification of oncogenes in order to 
silence or obliterate them.4  
		
The clustered regularly interspaced short 
palindromic repeats (CRISPR)-associated 
nuclease Cas9 genome editing system has 
been gaining attention as a novel method for 
genome editing, owing to its specificity, 
simplicity, versatility, and affordability. 
With proper guide RNA (gRNA)—a 
complementary base-pairing nucleotide 
designed to locate specific genomic loci in 
the sea of chromatin—it confers extensive 
gene deletion with less off-target effects. 
Numerous studies have demonstrated 
CRISPR/Cas9’s potential efficacy in the 
treatment of various cancers, prostate 
cancer included, through targeting of 
oncogenes in vitro.5-11 Implementation of 
CRISPR/Cas9 in clinical setting, however, 
remains a major challenge due to difficult 
delivery of the nuclease and associated 
guide RNA in vivo.12 	
Targeted cellular delivery of CRISPR/Cas9 
is therefore desired to obtain the genome-
editing system’s full potential. We sought to 
identify a highly-specific, efficient, and 
versatile method of delivery with adequate 
safety. We found that the transport of 
CRISPR/Cas9 with cationic liposome 
conjugated with RNA aptamer is a desirable 
delivery system for this. Cationic liposome 
acts as a carrier for the nuclease-gRNA 
complex with low toxicity. RNA aptamer 
acts as targeting ligand which can recognize 
cellular receptors with high affinity, 
therefore improving specificity and 
efficiency of delivery. The system is also 
highly flexible as RNA aptamers can be 





Material and Methods 
We used PubMed, Google Scholar, 
ClinicalKey, and ScienceDirect to search 
for the research paper and articles used in 
this literature review with the following 
keywords “CRISPR/Cas9”, “Prostate 
Cancer”, “Prostate Carcinoma”, “PLK1”, 
“Gene silencing or gene knockout”, “RNA 
aptamer”, “Oncogene”, “Cationic 
Liposome”. We searched for appropriate 
articles which matched the topic of our 
literature review. From those articles, we 
excluded articles that were not yet published 
such as “accepted manuscript” and “author 
manuscript”. Knowledge synthesis was 
done using those resources.   
Result and Discussion 
Pathogenesis of prostate cancer 
Prostate cancers usually develop from 
excessive androgen production. Binding of 
androgen to androgen receptors (AR) in 
prostatic cells induces expression of pro-
survival genes. Tumors that develop 
through this fashion exhibit androgen 
sensitivity, thus treatment using androgen 
receptor blocker effectively regresses the 
tumor size.1 
Unfortunately, most tumors will become 
androgen-resistant. This progression is 
promoted by several mechanisms, such as: 
(1) AR gene amplification; (2) mutations in 
the AR gene resulting in improper 
activation of the receptor; and (3) mutations 
in the alternative signalling pathway which 
cause the expression of pro-survival genes 
despite the absence of androgen.1 
One of the earliest events of genomic 
mutation in prostate cancer is the 
rearrangement of TMPRSS2-ERG gene. 
The excessive genomic rearrangement that 
occurs in prostate cancer cells may cause 
fusion of TMPRSS2 gene into ERG gene. 
		
This event is highly observed at 16-20% in 
Prostate Intraepithelial Neoplasm (PIN), 
40%-70% in prostate adenocarcinoma, and 
45%-86% in prostatic small cell 
carcinoma.2,3 
However, this fusion usually occurs in 
androgen-dependent prostate cancer. This is 
because TMPRSS2 is an androgen-
regulated promoter gene, thus the absence 
of androgen represses this gene, which in 
turn will repress ETS gene family (one of 
them being ERG) expression. ETS itself is a 
gene that is responsible for the invasiveness 
of prostate epithelial cells although it does 
not directly transform the cells themselves.1 Despite	the	constant	expression	of	TMPRSS2-ERG	in	later	stages	of	carcinoma,	it	is	highly	doubted	that	the	fusion	gene	has	a	major	role	in	 the	disease	progression since later stage 
cancers exhibit other androgen-independent 
pro-survival and anti-apoptotic genes, thus 
causing castration-resistant prostate 
cancer.2 
Other gene that contributes to androgen-
independent prostate carcinogenesis is Her-
2/neu gene. This is done through the 
activation of AKT pathway which provides 
androgen-independent AR activation. The 
activation of MAP kinase, AKT, and P13 
kinase pathways results in stabilization of 
AR which causes constant activation of AR 
without its ligand.2,4 In addition, Her-2/neu 
gene activation can increase cell adhesion 
capability, thus elevating the chance of 
tumor metastasis.2 
Another gene that is widely studied in the 
field of prostate cancer is MYC gene. This 
gene is thought to regulate 15% of all human 
genes. The expression of this gene results in 
cellular proliferation, thus overexpression 
of this gene due to mutation in the human 
prostate epithelial cell is linked to 
immortalization.13 
Moreover, the expression of stem cell genes 
(including Oct-4, Klf4, Sox2, and c-Myc) is 
associated with poor outcome. However, the 
expressions of both Klf4 and c-Myc genes 
in the prostate cancer are significantly 
overexpressed compared to normal prostate 
epithelial cells.14 The	exact	role	of	Klf4	is	still	unknown.	While	it	 is	 observed	 to	 promote	 carcinogenesis	 in	the	breast	and	skin	cancer,	Klf4	acts	as	tumor	suppressor	 in	 lung	 and	 skin	 cancer. 
However, it is certain that Klf4 prevents 
differentiation in embryonal stem cells. In 
the prostate cancer cells, the expression of 
Klf4 and c-Myc is higher compared to 
embryonic stem cells. Overexpression of 
Klf4 in the prostate carcinoma might be a 
step towards dedifferentiation of cancer 
cells, leading to a more malignant type of 
cancer.14 
Another pro-survival gene that plays a role 
in prostate oncogenesis is polo-like kinase 1 
gene (PLK1). PLK1 gene expression is 
highly enhanced in the tumor cells and is 
associated with poor outcome. The 
inhibition of PLK1 increases cell apoptosis 
and necrosis rate.15 
 
Introducing CRISPR/Cas9 
CRISPR (Clustered Regularly Interspaced 
Palindromic Repeats) is a prokaryotic-
derived mechanism of adaptive immunity 
towards invasion of foreign nucleic acid 
such as viral nucleotides and plasmids.16 
Cas9, one of the CRISPR-associated 
proteins, is a nuclease capable of cutting 
both strands of DNA.17 This system can 
recognize and cut non-self DNA, where 
small sequences of the cut DNA will later 
be incorporated into the CRISPR array in 
the host’s genome, creating a memory for 
the adaptive immune system to protect the 
		
host from further invasion.18 Today, this 
system has been utilized in gene-editing 
field as it can correct errors in genome as 
well as turn on and off genes quickly and 
selectively. Moreover, this system is 
considered as cheap and easy to use.19  
It is important to understand that there are 6 
types of CRISPR-Cas system which are 
classified into 2 classes based on the 
diversity on the nature of the effector 
nuclease:18 a multi-subunit protein complex 
of nuclease for class 1 (such as the CRISPR-
associated complex for antiviral defense 
(CASCADE) complex assisted by the Cas3 
helicase20, the Csm complex21, or the Cmr 
complex22 within type I and type III 
CRISPR-Cas system); and a single large 
polypeptide of nuclease for class 2 (such as 
the  Cas9 within type II and Cpfl within type 
V systems).23 Hence, CRISPR/Cas9 is 
known as the CRISPR-Cas type II and is a 
part of class 2. In addition, Cas9 needs 
tracrRNA to activate the enzyme, as it is 
normally in a non-active form (Apo-
Cas9).24 
Compared to the other types, type II 
CRISPR mechanism is the most studied and 
is considered unique, as it needs only one 
Cas protein (Cas9) for gene editing.25	The 
simplicity of the type II CRISPR-Cas 
system, requiring only two major 
components (Cas9 along with the gRNA), 
makes this system susceptible for genome 
editing.26 
 
Comparison of CRISPR/Cas9 with Other 
Genome Editing Tools 
Other genome editing tools, the Zinc-finger 
nucleases (ZFNs) and transcription 
activator-like effector nucleases (TALENs), 
can both facilitate targeted Double Strand 
Breaks (DSBs) at specific loci like Cas9 
nuclease system.27 Until now, Cas9 has 
been considered as a major breakthrough in 
the field of genome editing,28 as it offers 
several potential advantages when it is 
compared to ZFNs and TALENs. First, 
Cas9 has an advantage on target design 
simplicity as it relies on gRNA which can 
be easily retargeted new DNA through the 
customization of 20-nt sequence, while both 
ZFNs and TALENs use DNA-binding 
domain, an independently folded protein 
domain which recognizes double- or single-
stranded DNA as targets, that are considered 
more expensive and time-consuming. 
Second, Cas9 system is super-efficient as it 
can target multiple genomic loci at once by 
injecting multiple gRNAs. Third, Cas9 
offers a blunt cut in the target sequence, 
where in contrast TALENs cleave non-
specifically between the pair of TALEN 
monomer-binding sites.27,28,30 
 
CRISPR/Cas9: Insights into the 
Structure and Mechanism of Action 
Overall, the mechanism of action of the 
CRISPR-Cas system can be divided into 
three stages: adaptation, expression and 
maturation, and interference.18 The 
adaptation stage is where the unutilized-
invading nucleic acids are turned into short 
fragments of DNA. These fragments will 
then be integrated into the CRISPR arrays 
within the host genome as new spacers, with 
the help of Cas1 and Cas2 proteins, thereby 
creating a genetic record of prior infection 
which provides protection to the host 
towards the same invader. Note that the 
sequences from which the spacers are 
derived from, prior to the merging into the 
CRISPR array, are called the 
protospacers.18,31 The expression and 
maturation stages are the stages where the 
CRISPR array is transcribed and processed 
		
into smaller units of spacer-contained 
CRISPR-RNAs (crRNA) then is combined 
with the Cas proteins to form an active Cas-
crRNA complex.18 The interference stage is 
where Cas-crRNA complex scans the cell to 
search for foreign nucleic acid targets that is 
complementary to the base-pairing of the 
crRNA sequence. Successful recognition 
will lead to the cleavage and degradation of 
the target nucleic acid. The Cas9 does not 
recognize spacers incorporated in the host 
genome as it does not possess the 
protospacer adjacent motifs (PAM), a short 
sequence of DNA 5′-NGG-3′.24 Indeed, 
PAM plays a very important role in the 
recognition of self and non-self DNA as it is 
only present in the foreign DNA, sparing the 
CRISPR system to delete itself.18,24  
CRISPR/Cas9 relies on the extensive 
complementary base-pairing via the 20-nt 
guide sequence on the single guide RNA 
(sgRNA) to locate specific genomic loci in 
the sea of chromatin. The presence of PAM 
directly downstream the 3’ of the 20-bp 
target sequence is required for it to be 
recognized and adhered by the Cas9. Note 
that different Cas9 orthologs have different 
PAM sequence. For instance, wild-type S. 
pyogenes Cas9 (SpCas9) requires a 5’-NGG 
PAM. This requirement does not severely 
limit the targeting range of the Cas9, as 
some studies show that in the human 
genome, sites of 5’-NGG-3’ can be found 
every 8-12 base pairs.27,32,33 
CRISPR-Cas9 system is then adapted for 
uses in the genome editing tools. The guide 
RNA used in this system is a 18-20 
nucleotides long of sgRNA which arises 
from merging crRNA with a part of the 
tracrRNA into a hybrid RNA.34 Transport of 
cas9 nuclease and a sgRNA will generate  
double stranded-DNA break at the target 
chromosomal location in eukaryotic cells. 
The Cas9-induced Double Strand Breaks 
(DSBs) is re-repaired by two mechanisms: 
NHEJ (Non-homologous End Join) and 
HDR (Homologous Directed Repair). NHEJ 
is a cell’s natural way to repair a cleaved 
DNA in which the ends of the DSB are 
rejoined through endogenous DNA repair 
system. This repair may cause random 
mutations that results in the frameshifts and 
creation of a premature stop codon, thus it is 
considered as error-prone. Moreover, HDR 
provides a single-stranded template of 
oligonucleotide in the form of 
oligodeoxynucleotide (ssODN) which has 
the ability to provide high fidelity and 
precise gene editing.16,27 
Furthermore, the possible mechanism to 
deactivate the gene is by using the 
deactivated version of Cas9 (dCas9) which 
has the ability to recognize and bind to the 
target DNA, but loses its ability to cleave 
the sequence, hence its purpose is to block 
transcription and repress target gene 
expression.35 
 
CRISPR/Cas9 Application: Inactivation 
of Mutations in Cancer 
Genetic mutation is one of the hallmarks of 
cancer development. Until now, there has 
been more than 140 cancer driver genes 
described.36,37 Therefore, identification of 
all genes in the actual tumor cells are 
emerging, yet the exact function and role of 
most mutations have not yet been 
resolved.38 Moreover, despite its ability to 
reduce the development of cancerous cells 
and its capability to increase lifespan to a 
maximum of five years, the current cancer 
treatments (chemotherapy, radiotherapy and 
surgery) have harmful side effects and 
toxicity although it significantly reduces the 
quality of life. Using CRISPR/Cas9 
technology, a powerful tool known to its 
		
capability to correct many mutations at once 
in a cell's genome, researchers hope to 
resolve the functional role of the mutations 
in the cancer cells through the targeting of 
mutated genes, elucidating gene function 
involved in tumor progressions, correcting 
mutations, inactivating activated oncogenes 
or activating inactive cancer suppressor 
genes, which overall has shown promise 
towards reliable long term cancer therapy.39 
 
CRISPR/Cas9-mediated gene silencing in 
prostate cancer models 
Several studies have demonstrated the 
potential efficacy of CRISPR/Cas9 system 
in reducing the malignancy of prostate 
cancer models through silencing of genes 
which are believed to be involved in the 
tumors’ pathogenesis and progression. 
These target genes include NANOG and 
GPRC6A.9,10 
NANOG is an essential transcription factor 
in the embryonic stem cells, providing 
pluripotency and driving embryonic 
development.40 However, it is also 
expressed in various cancers, including 
ovarian cancer, colorectal cancer, and 
prostate cancer.41-45 Increased NANOG 
expression is observed in cancer stem-like 
cells (CSCs), whose presence in tumors is 
believed to increase lethality.8,10,13 
Consequently, increase of NANOG 
expression has been linked to poor 
prognosis in many cancers and increase in 
Gleason score, a poor indicator for prostate 
cancer.40,44-46 
Kawamura et al (2015)9 conducted 
CRISPR/Cas9-mediated gene knockout of 
NANOG and NANOGP8—a significant 
NANOG pseudogene—in DU145 prostate 
cancer cell line, which resulted in 
significant attenuation of malignant traits.9 
Sphere-forming capacity of knockout 
cells—a trait highly related to 
tumorigenicity—was decreased to 50% 
compared to parental (control) DU145 
cells.9,47 Migration of knockout cells was 
decreased by 40-60%.41 Knockout of this 
gene also increased drug sensitivity, a 
finding consistent with other studies.9,48 In 
vivo tumorigenicity was also decreased 
considerably following NANOG knockout; 
tumor formed within mice implanted with 
knockout cells had a much lower volume 
than control after 7-week-long observation.9 
GPRC6A is an abundantly expressed G-
protein-coupled receptor which regulates 
many biological processes, such as energy 
metabolism, sexual reproduction, and bone 
formation. Its ligands include amino acids, 
calcium, zinc, testosterone, and 
osteocalcin.49,50 Implication of GPRC6A’s 
involvement in the prostate cancer is based 
on numerous evidences, including: (1) its 
expression is increased in prostate cancer 
cell lines; (2) its activation results in 
proliferation and migration of prostate 
cancer cells; (3) high serum level of its 
ligand namely osteocalcin, is used as a 
biomarker for prostate cancer.49,51-53 
Ye et al (2017)10 evaluated GPRC6A’s role 
in the prostate cancer’s progression both in 
vitro and in vivo. CRISPR/Cas9 was used to 
target GPRC6A gene in PC-3 prostate 
cancer cell line. Modified and parental 
(control) cell lines were then treated with 
osteocalcin to assess the receptor activity. 
Treating modified cells with osteocalcin did 
not induce proliferation well and the 
expression of proliferation marker PCNA 
was decreased. Osteocalcin-induced 
cellular migration was also reduced 
considerably in modified cells. In vivo 
cancer progression was also inhibited; 
		
osteocalcin treatment to mice implanted 
with modified PC-3 cells failed to increase 
tumor size and weight.10 
Targeted cellular delivery of 
CRISPR/Cas9 system with RNA 
aptamer-cationic liposome chimera To utilize CRISPR/Cas9-based therapy 
well, the transport of the system to the 
appropriate tissue or cell type is of 
paramount importance. The success of 
CRISPR/Cas9 treatment therefore relies on 
the development of carriers, whose delivery 
in vivo remains difficult. Thus, 
CRISPR/Cas9-based therapy is often 
considered non-applicable in the clinical 
setting.54  
Conventional delivery methods of 
CRISPR/Cas9 involve physical 
introduction of the system into the nucleus 
and viral-vector-mediated insertion of the 
Cas9-gRNA complex.54 Physical delivery is 
more suitable in vitro as it is simpler and 
highly reproducible, but less suitable in vivo 
as subject’s physiology and pathological 
status vary.55,56 Viral vectors are highly 
efficient, but bear safety concerns regarding 
potential immunogenicity and 
carcinogenicity. In addition, some viral 
vectors have limited capacity to carry large 
enzymes like Cas9 and limited number of 
cell types which can be infected.57,58 Thus, 
the usage of non-viral vectors as delivery 
alternative is done in the consideration of 
their low immunogenicity, ability to carry 
larger cargo, and simpler large-scale 
production.  
Ideal in vivo delivery system of 
CRISPR/Cas9 needs two components: (1) a 
carrier which can protect the cargo from 
degradation in the bloodstream; (2) a 
targeting ligand to recognize specific 
receptors on the appropriate target cell.11,54  
An excellent carrier candidate is cationic 
liposome: a phospholipid-bilayer vesicle 
surrounding an aqueous core. The gRNA-
nuclease complex can be incorporated 
inside, where it will be protected.59 Cationic 
liposomes provide stable storage and low 
immunogenicity. They are well studied, 
being the first non-viral vectors to enter 
clinical trials.59 However, cationic 
liposomes may induce inflammatory 
response and have low specificity, reducing 
transfection efficacy.5l,60 Thus, in vivo 
application of cationic liposome-based 
delivery is still restricted. 
Modification of cationic liposome’s surface 
with targeting ligand can help improve its 
efficacy. A promising targeting ligand is 
aptamer: small, single-stranded RNA or 
DNA oligonucleotide of 20-60 nucleotides. 
Aptamers bind target molecules with high 
specificity and affinity, making them 
comparable to antibodies. Furthermore, 
they have easier and cheaper production, 
lowly immunogenic, non-toxic, and bind to 
various molecules, making them an 
exceptional targeting ligand.61,62 Of all 
aptamers, prostate-specific membrane 
antigen (PSMA) aptamers, such as RNA 
aptamer A9 and A10, are the most 
studied.63,64 
Aptamers can be attached to the lipid heads 
of liposomes with the help of a hydrophilic 
polymer namely polyethylene glycol (PEG) 
as seen in Figure 1. In addition to mediate 
conjugation of aptamers, coating liposomes 
with PEG also improves stability. 
Mononuclear phagocyte system cannot 
recognize the ‘stealth’ hydrophilic surface 
of PEG, thus preventing removal of 
liposomes. PEG also prevents attachment of 
		
proteins and opsonins in the blood. 
Therefore, blood clearance is avoided and 
circulation time is improved, allowing more 
efficacious targeting & delivery.54,59,60 
Implementation of RNA aptamer in tumor 
treatment has been reported. A gp120 
aptamer-silencing RNA (siRNA) chimera 
was able to deliver siRNA targeting HIV-1 
tat/rev common exon.62 The same chimera 
was also able to deliver siRNA into tumor 
cells.62-64 RNA aptamer-conjugated cationic 
liposome has been used to deliver 
anticancer drug doxorubicin into prostate 
cancer cells in vivo.68 However, the delivery 
of CRISPR/Cas9 using RNA aptamer has 
not been reported. 
Zhen et al. undertook this challenge in their 
2016 study, incorporating the RNA 
aptamer-cationic liposome to deliver 
CRISPR/Cas9 which targeted prostate 
cancer.11 The RNA aptamer A10, which 
targets PSMA, was used, and LNCaP cell 
line was selected because of the presence of 
PSMA on their surface, as opposed to PC-3 
cell line.11,69 
Packaged CRISPR/Cas9-gRNA was 
targeted to the pro-survival gene polo-like 
kinase 1 (PLK1). PLK1 phosphorylates 
numerous proteins during mitosis. Its role in 
cellular proliferation is critical; PLK1 is 
only expressed in dividing cells, with 
highest expression during G2/M phase.70-72 
Mutation and subsequent overexpression of 
PLK1 result in chromosomal instability, 
aneuploidy, and improper cell division—all 
of which are the hallmarks of cancer 
cells.70,71 Accordingly, PLK1 
overexpression is observed in many 
cancers, such as breast cancer, rectal cancer, 
and prostate cancer.72-75 
PLK1 has been a target of cancer treatment, 
and numerous studies have demonstrated 
that inhibition of PLK1 induces apoptosis, 
tumor growth reduction, and reduced 
proliferation.70,76,77 Thus, it is expected that 
CRISPR/Cas9-mediated knockout of PLK1 
will reduce malignancy. Consequently, the 
success of aptamer-liposome chimera as a 
delivery system can be evaluated via 
attenuation of malignant traits. The results 
were favorable, as described below.11  
(1) A10-liposome-CRISPR/Cas9 chimera 
was able to bind cell significantly with 
high specificity. Binding of A10-liposome-
CRISPR/Cas9 chimera to PSMA showed 
significant competition with PSMA 
antibody. This indicates that the chimera’s 
binding to prostate cells is comparable to an 
antibody. The chimera’s binding strength 
was similar to A10 aptamer alone, showing 
that the aptamer retained its binding 
ability.11  
(2) A10-liposome-CRISPR/Cas9 chimera 
had substantial in vitro gene silencing 
effect, down-regulating PLK1 mRNA 
transcription significantly (63%). The 
down-regulation achieved was the highest 
of all CRISPR/Cas9 reagents formulations, 
showing the chimera’s efficacy in 
transfecting CRISPR/Cas9. Without A10, 
the liposome carrying CRISPR/Cas9 had 
similar silencing effect as lipofectamine-
2000 (a transfection reagent), demonstrating 
that on its own the liposome had 
considerable transfection ability, which was 
improved with A10 aptamer.11 
(3) Cellular uptake assay showed that the 
A10-liposome-CRISPR/Cas9 chimera 
mediated the most efficient delivery of 
fluorescent-labeled CRISPR/Cas9. 
Fluorescent signal from cells treated with 
A10-liposome-CRISPR/Cas9 chimera was 
		
the strongest, showing that uptake of 
CRISPR/Cas9 was best achieved through its 
delivery. This also means that the strong 
gene silencing effect from the A10-
liposome-CRISR/Cas9 chimera resulted 
from the efficient delivery.11  
(4) Cell viability was the lowest following 
A10-liposome-CRISPR/Cas9 chimera 
treatment. As established before, 
knockdown of PLK1 is expected to reduce 
LNCaP cells’ survival. Therefore, efficient 
delivery of PLK1-targeted CRISPR/Cas9 
would reduce cell viability the most, as 
provided by A10-liposome-CRISPR/Cas9 
chimera. Yen et al. also demonstrated that 
the aptamer-liposome chimera is inherently 
non-toxic.11 
(5) A10-liposome-CRISPR/Cas9 chimera 
promoted regression of tumor in vivo. 
Mice with xenograft tumor (derived from 
LNCaP cells) were treated with different 
CRISPR/Cas9 formulations for 27 days. 
The A10-liposome-CRISPR/Cas9 chimera 
exhibited the most significant tumor 
regression (0.40 cm3 to 0.15 cm3). Free 
CRISPR/Cas9 and A10-liposome-
scrambled CRISPR/Cas9 (no gRNA 
included) did not reduce tumor volume, 
showing importance of proper 
CRISPR/Cas9 delivery and the need for 
targeting PLK1. Importantly, neither 
mortality nor significant change of mouse 
body weight were observed after 27 days of 
treatment.11 
(6) A10-liposome-CRISPR/Cas9 chimera 
had low immunogenicity. IFN-α and IL-12 
levels of mice were assessed to determine 
immunogenicity. Compared to positive 
control, all formulations conferred low 
immunogenicity. However, adding A10 to 
the liposome chimera resulted in even lower 
cytokine levels, suggesting that A10 helps 
to prevent non-specific induction of 
immune response by increasing 
specificity.11 
As shown by Ye et al.11, in vitro observation 
of A10-liposome-CRISPR/Cas9 chimera’s 
ability to silence gene and decrease cell 
viability was consistent with in vivo efficacy 
of the delivery system in promoting tumor 
regression. This may result from the 
enhanced binding of the chimera and the 
consequent improvement of Cas9-gRNA 
complex uptake. Moreover, the chimera 
confers no significant immunogenicity. 
Therefore, targeted cellular delivery of 
therapeutic CRISPR/Cas9 using RNA 
aptamer-cationic liposome chimera may 
help the implementation of CRISPR/Cas9 in 
clinical setting.  
Limitations of this method 
Despite its potential, CRISPR/Cas9 also 
have several limitations. First, similar to 
other nucleases, Cas9 has the potential to 
cleave off-target DNA targets, although at 
reduced frequencies.33,78 A double nicking 
strategy can be used as a strategy to 
minimize off-target mutagenesis. However, 
it is important to understand the structure of 
the Cas9. The Cas9 nuclease is a bi-lobed 
structured protein consists of both alpha-
helical and nuclease lobe, connected by a 
single bridge helix. The gRNA itself is 
located between those two lobes. The 
nuclease lobe has two other domains called 
the RuvC whose function is to cleave non-
target DNA strand and the NHN nuclease 
whose function is to cleave target DNA 
strand.78 Normally, the Cas9 will perform a 
double strand break on the foreign DNA 
site, yet mutation of the domains, either the 
RuvC or HNH will result into a single strand 
break. These mutants are known as Nickase, 
which can cut either complementary or on-
		
complementary DNA.79 As single-stranded 
nicks will be repaired, DSB would only 
possible if both sgRNA are able to 
successfully cleave the defined targets and 
hence prevent un-wanted mutagenesis. 
These strategies are then considered 
promising in the attempt to increase the 
specificity in genome editing using 
CRISPR/Cas9.27 
Second, not every cancer cell has the same 
mutation therefore this therapy is highly 
specific since the A10-Liposome-
CRISPR/Cas9 without PLK1 gene exhibit 
lower tumor volume reduction. This means 
this method will only work if the gene 
mutation in the tumor matches with the 
gRNA of the A10-Liposome-CRISPR/Cas9 
system. 
Third, the aptamer-liposome chimera 
requires understanding regarding the target 
cell receptor because aptamer is very 
specific towards a certain receptor. Without 
the knowledge of the receptor and ligand, it 
is not possible to create the correct aptamer-
liposome chimera. 
Fourth, there are some limitations in this 
method due to the vulnerability towards 
opsonization of the liposome, accelerated 
blood clearance, immune response, and lack 
of research in this field. This problem can be 
solved by incorporating cholesterol into the 
phospholipid bilayer. Further research 
should be done to know the solution to these 
problems, its clinical efficacy, and side 
effects. 
Last, this gene editing system is still a very 
new technology. There are not many 
researches about CRISPR/Cas9 with 
aptamer-liposome chimera. Another 
research should be done to reinforce and 
support the researches used in this literature 
review.  
However, if this method is combined with 
other conventional therapy of prostate 
cancer, it might help in reducing metastatic 
prostate cancer. While conventional therapy 
can be used in androgen-sensitive prostate 
cancer, A10-Liposome-CRISPR/Cas9 
system can be used as androgen-resistant 
metastatic prostate cancer to specifically 
target prostate cancer cells that have 
metastasized to another part of the body. 
Conclusion 
The therapy of prostate cancer with 
CRISPR/Cas9 as a cutting edge genome 
editing technology shows promising future 
thanks to its affordability and specificity. 
Both in vivo and in vitro studies have 
demonstrated its potential in reducing 
malignancy and promoting tumor 
regression. However, its clinical 
implementation remains difficult due to 
challenges in delivering the Cas9-nuclease 
complex to target tissue. Using targeted 
cellular delivery system with aptamer-
conjugated liposome, a well-established 
carrier, can be a way to work around this 
problem. Modifying liposome surface with 
aptamer as targeting ligand can improve its 
efficacy through increased specificity 
towards target tissue. Attachment of RNA 
aptamer to liposome surface with PEG helps 
increase stability, reduce blood clearance, 
and increase circulation time. This approach 
can be used as the therapy of many diseases 
by targeting various cell types with the 
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Appendices 
Figure 1. Schematic representation of RNA aptamer-cationic liposome chimera as a targeted delivery 
system of CRISPR/Cas9. The phospholipid bilayer, which encloses an aqueous core containing the 
gRNA-nuclease complex, has aptamers attached onto its surface with the help of polyethylene glycol 
(PEG), which also provides stability and increases circulation time. 
Adapted from: Schiener M, Hossann M, Viola JR, et al. Nanomedicine-based strategies for treatment of 
atherosclerosis. Trends in molecular medicine. 2014 May 31;20(5):271-81. Figure 1, Features of a 
multifunctional liposome; p. 273. 	
